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The AF-6 protein is a multidomain protein that contains two
potential Ras-binding domains within its N terminus. Because of
this feature, AF-6 has been isolated in both two-hybrid and
biochemical approaches and is postulated to be a potential Ras-
effector protein. Herein, we show that it is specifically the first
Ras-binding domain of AF-6 that mediates this interaction and that
the Ras-related Rap1A protein can associate with this motif even
more efficiently than the oncogenic Ha-, K-, and N-Ras GTPases. We
further demonstrate that both Ras and Rap1 interact with full-
length AF-6 in vivo in mammalian cells and that a fraction of Rap1
colocalizes with AF-6 at the membrane. Dominant active Rap1A, in
contrast to Ras, when introduced into epithelial MDCK and MCF-7
cells, does not perturb AF-6-specific residency in cell–cell adhesion
complexes. In a pursuit to gain further understanding of the role
of AF-6 in junctions, we identified profilin as an AF-6-binding
protein. Profilin activates monomeric actin units for subsequent
polymerization steps at barbed ends of actin filaments and has
been shown to participate in cortical actin assembly. To our
knowledge, AF-6 is the only integral component in cell–cell junc-
tions discovered thus far that interacts with profilin and thus could
modulate actin modeling proximal to adhesion complexes.
The Ras proteins are signal-transducing GTPases that cyclebetween GDP-bound inactive and GTP-bound active states,
relaying signals from various membrane receptors to the nucleus
to mediate cellular activities such as cell growth control (1). The
importance of Ras genes in the etiology of human cancers is
made evident by the frequent findings of activated ras oncogenes
in a wide variety of cancers. These cancer cells, as well as
oncogenic Ras-transformed cell lines, apart from their deregu-
lated proliferation, are characterized by changes in morphology
and cell–cell adhesion (2, 3). Several downstream effector
molecules mediating Ras’ effect on proliferation have been
identified, including Raf, RalGDS, and PI3-kinase proteins (1).
Some of these effector molecules are shared by a closely related
Ras GTPase, Rap1, which contains a virtually identical effector
loop region (4). The first Rap GTPase was identified originally
in a screen for revertants of the morphology exerted by K-Ras-
transformed cells (5), which suggested a Ras-antagonizing ef-
fect. However, more recent studies support fundamental differ-
ences between Ras- and Rap1-controlled signaling pathways (4,
6). First, Rap1A, in contrast to Ras, is found largely in mid-Golgi,
endocytic vesicles, and lysosomal vesicles, indicating different
cellular functions of the proteins (6). On a molecular level, Rap’s
activation seems to be dictated by a growing number of exchange
factors that do not act on the prototypic oncogenic Ras GTPases
(6–8). Finally, in developmental systems, the functions of Rap
proteins seem to be related primarily to morphological and
differentiative events, rather than to those that govern prolifer-
ation and cell-fate specification, phenomena that often require
signaling via conventional Ras proteins (9, 10).
In addition to the Ras-binding proteins described above, the
human AF-6 protein has been identified as a potential Ras-
interacting molecule by two different approaches: one based
on a two-hybrid interaction assay in yeast (11); the other one
based on an affinity purification protocol (12). The AF-6 gene
was also found to be fused to the ALL-1 gene in a subset of
acute lymphoblastic leukemias caused by chromosomal (t 6;11)
translocation events—hence the name ALL-1 fused gene on
chromosome 6 (13). Subsequent database analysis led to the
prediction of an array of motifs, such as two N-terminal
Ras-binding domains (RBDs; ref. 14), U104 and DIL motifs
that were described initially in microtubule and actin-based
motor proteins, respectively (15), and a PDZ domain followed
by an extended C-terminal tail interspersed with proline-
enriched patches. The corresponding molecule in rat, namely
afadin, is present in two splice variants, the larger of which,
l-afadin, was purified as a protein from rat brain extracts
associated with filamentous actin. This affinity for F actin
resides in a sequence that is unique to l-afadin’s C terminus,
but is absent in the shorter splice variant, s-afadin, which
represents the actual AF-6 homologue (16).
The issue of whether members of the Ras-family of GTPases
use AF-6 as a bona fide effector in specific cellular events,
however, remains unresolved. Various subcellular localization
experiments performed in polarized epithelial cells and tissue
sections of intestinal epithelia suggest its distinct residency in
cell–cell junctional complexes (16–18). In the former system,
AF-6 was assigned to tight junctions, because it was found to bind
Zona Occludens (ZO-1), an integral component of tight junc-
tional complexes (17, 19). In the latter, the rat AF-6 homologue
seemed to be tethered to adherens-based adhesion complexes
(16, 18). Both studies, however, suggest that AF-6, along with
other molecules, constitutes a physical link between membrane-
located adhesion molecules and the cortical actin cytoskeleton.
Consistent with this suggestion are more recent findings dem-
onstrating that the Drosophila homologue of AF-6, Canoe, is
targeted to junctional complexes in embryonic epithelia (20).
Canoe was first identified by virtue of its severe rough eye
phenotype and has been shown to interact genetically with the
Notch signaling pathway, a pathway that determines various cell
fates in a multitude of developmental processes (21).
Herein, evidence is presented that the Rap1A GTPase, in
addition to the classical oncogenic Ras proteins, can interact
with AF-6 in two-hybrid assays, as well as in vivo, and that it is
the RBD1 domain that confers this binding capacity. We further
show that a fraction of dominant active Rap1A colocalizes with
AF-6 at the membrane. These data suggest that AF-6 may
function as a Rap1 effector molecule. In contrast to oncogenic
Ras, cells stably expressing constitutively active Rap1A retain
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AF-6 at the cellular junctions. It is likely that specific Ras
proteins target AF-6 in different developmental and cellular
situations to elicit distinct effects. Moreover, in an endeavor to
elucidate the role of AF-6 in junctional complexes further, we
isolated profilin as an associated protein. Profilin plays a critical
role in actin polymerization events, and apart from the F actin
association of l-afadin mentioned above, this interaction might
provide another more dynamic link between junctional com-
plexes and the actin cytoskeleton.
Methods
Plasmids and Abs. For the construction of pGAD AF-6 N-terminal
domains, AF-6N (amino acids 1–368), AF-6-RBD1 (amino acids
1–140), and AF-6-RBD2 (amino acids 181–368) were PCR
amplified from pBSK-AF-6 (a gift from E. Canaani, Weizmann
Institute, Rehovot, Israel) and subcloned into pGAD1318 (22).
PI3Kd-RBD was PCR amplified from pBSK-PI3Kd (a gift from
B. Vanhaesebroeck, Ludwig Institute, London) and subcloned
into pGAD1318. LexA DNA-binding domain (LBD) Rap1E63
and Rap1N17 constructs were generated by inserting PCR-
generated Rap1E63 and Rap1N17 cDNAs into a pLexVJL10
(22). For the construction of the pGAD-profilin constructs,
profilin I and profilin II were PCR amplified from a profilin
two-hybrid clone and from expressed sequence tag 663,927,
respectively, and subcloned into pGAD1318. The plasmids
pGADGH c-RafN, pGAD1318 RalGDS-RBD, LBD Ha-
RasV12, and LBD RasN17 have been described (23, 24). Full-
length Ha-RasV12 and Rap1E63 were subcloned into the pB-
abe-puro and pDCR vectors (23, 25). pcDNA AF-6-myc was
generated by cloning AF-6 lacking the stop codon into
pcDNA3.1yMyc-His3 (Invitrogen). To construct glutathione
S-transferase (GST)–AF-6 fusion proteins, AF-6 fragments ob-
tained by PCR were subcloned into pGEX-4T1. mAbs against
hemagglutinin (HA; clone 12CA5) and Myc (clone 9E10) were
purchased from Roche Molecular Biochemicals and Oncogene
Science, respectively. Mouse anti-Ras, Rap1, and b-catenin Abs
were obtained from Transduction Laboratories (Lexington,
KY), and mAb against ZO-1 was purchased from Zymed.
Polyclonal Ab against AF-6 (amino acids 1,130–1,612) and
profilin were kindly provided by K. Kaibuchi (Nara Institute,
Nara, Japan) and T. Pollard (Salk Institute, La Jolla, CA),
respectively. Polyclonal Ab against an AF-6-specific peptide
(CGRVEQQPDYRRQESRTQD, amino acids 561–576) was
generated as described by Harlow and Lane (41).
Retroviral-Mediated Gene Transfer. For the generation of MDCK-
RasV12 and MDCK-Rap1E63 stable cell lines, retroviral-
mediated gene transfer was performed as described (26).
LinX-A cells (a gift from Greg Hannon, Cold Spring Harbor
Laboratory) were transfected with 6 mg of pBabe Ha-RasV12 or
pBabe Rap1E63 retroviral plasmids, and the resulting virus was
used to infect MDCK cells. Infected cell populations were
subjected to puromycin selection (10 mgyml) for 3 days. Expres-
sion of the GTPases was confirmed by Western blot analysis.
Yeast Two-Hybrid Protein–Protein Interactions. The yeast reporter
strain L40 (22) was used for all two-hybrid analyses. The assays
to detect protein–protein interactions were performed as de-
scribed (22). For the yeast two-hybrid screen, a C-terminal
fragment (amino acids 910–1,612) of AF-6 fused to LexA to
generate pLexA-AF-6C was cotransformed into L40 with a
Jurkat cDNA library fused to Gal4-activation domain (GAD) in
pGAD1318 (11).
GST Pull-Down, Immunoprecipitation Assays. GST AF-6 fusion pro-
teins were expressed in BL21 Escherichia coli cells, extracted in
bacterial lysis buffer, and purified on glutathione-Sepharose
resin (Amersham Pharmacia). Whole-cell lysates of MDCK cells
were incubated with 250 mg of fusion protein, and bound
proteins were eluted with 50 ml of SDS sample buffer. Proteins
were separated by SDSyPAGE and transferred to nitrocellulose
membrane. Profilin protein was visualized with a polyclonal
anti-profilin Ab and enhanced chemiluminescence (Amersham
Pharmacia). Cos1 cells were cotransfected with pcDNA-AF-6-
myc and pDCR Ha-RasV12 or pDCR Rap1E63 by using Fugene
(Roche Molecular Biochemicals). At 48 h after transfection, the
cells were washed twice with PBS and lysed in lysis buffer (27).
The supernatants were precleared by incubation with protein
G-agarose beads, nutated with 7 mg of anti-HA Ab overnight at
4°C, and then coupled with 30 ml of protein G-agarose for 1 h.
The beads were washed five times with lysis buffer, and the
proteins were separated by SDSyPAGE. After transfer to ni-
trocellulose membrane, coimmunoprecipitated AF-6 was de-
tected with anti-myc mAb and enhanced chemiluminescence.
Fluorescence Microscopy. Cells were plated on coverslips and
treated for immunofluorescence as described (28). x,y plane
images were collected at 0.5-mm steps through the entire z
dimension of labeled cells with a Noran Instruments (Middleton,
WI) XL laser scanning confocal attachment mounted on an
upright Nikon Optiphot (340).
Results
Interaction Between Rap1 and AF-6. We previously identified pep-
tides, comprising amino acids 1–180 and 1–205 of rat and human
AF-6, respectively, in yeast two-hybrid screens looking for
oncogenic Ras (Ha-RasV12)-interacting proteins (11). Data-
base searches revealed that the complete AF-6 protein contains
two predicted RBDs: the first comprising amino acids 39–133;
the second containing amino acids 256–348 (14). To assess
whether both domains are able to interact with AF-6, we
constructed LexA DNA-binding fusion constructs expressing the
first (RBD1), second (RBD2), or both RBDs (AF-6N) of human
AF-6. As shown in Table 1, AF-6N and the first domain (RBD1),
with even higher affinity, associated with Ha-RasV12. The
second domain (RBD2) failed to bind to Ha-RasV12. Similar
results were obtained with K-Ras and N-Ras; however, N-Ras
showed a weaker interaction (data not shown). We also inves-
tigated a possible association between the Ras-related protein
Rap1 and AF-6 and noticed that the strength of interaction
between Rap1 and AF-6 exceeded that exerted by RasyAF-6
complexes (Table 1). Both wild-type and constitutively activated
(CA) mutant forms of Ha-Ras and Rap1 interact with AF-6;
however, none of the dominant-negative mutant forms showed
binding activity toward AF-6. A similar binding profile has been
demonstrated between Ras and its well established effector, Raf
(24). Furthermore, we made use of the two-hybrid system to see
Table 1. Interaction between RasyRap1 and AF-6
LBD fusion
b-Galactosidase activity of GAD-fused AF-6 domain
AF-6N AF-6-RBD1 AF-6-RBD2
RasV12 99.0 6 1.6 210.0 6 1.8 0.7 6 1.4
RasN17 0.6 6 1.4 0.9 6 1.4 0.6 6 1.1
RapE63 120.0 6 1.7 350.0 6 1.9 1.2 6 1.1
RapN17 0.7 6 1.7 0.8 6 1.9 0.9 6 1.1
Lamin 0.7 6 1.3 0.8 6 1.1 0.7 6 1.5
Interaction between RasyRap1 and AF-6. The AF-6N, AF-6-RBD1, and AF-
6-RBD2 GAD fusion products were transformed individually into the yeast
reporter strain L40 with LBD fusions containing constitutively active and
negative mutant forms of Ha-Ras and Rap1, as well as lamin as a negative
control. Transformants were grown in selective synthetic medium, and b-
galactosidase activity was assayed with O-nitrophenyl-b-galactosidase; values
(miller units) are the means 6 SD of triplicate determinations.
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how AF-6 compares to c-Raf, RalGDS, and d-PI3-kinase in
terms of its ability to bind to Ras and Rap1. As shown in Fig. 1,
RasV12 is able to interact with all targets, the strongest inter-
action being with c-Raf. CA Rap1E63 shows strong interaction
with AF-6 and RalGDS; however, no association was observed
with d-PI3-kinase, and only very weak interaction was seen with
c-Raf. These results indicate that both GTPases, Ras and Rap1,
use effector molecules that are only partially identical and that
they exhibit differential binding profiles toward the targets listed
above.
Although an in vivo interaction between oncogenic Ras and
full-length AF-6 has been reported (27, 29), this interaction
remained to be defined for Rap1 and AF-6. To assess whether
Rap1 interacts with AF-6 in mammalian cells, myc-tagged
full-length AF-6 protein was coexpressed with HA-tagged
Rap1E63 in Cos1 cells. HA-tagged Ha-RasV12 was included as
a positive control. Cos cells were used, because the introduction
of wild-type AF-6 cDNA into MDCK and MCF7 cells did not
allow high levels of expression. As shown in Fig. 2A, GTPase-
bound AF-6 could be detected by blotting with an anti-myc Ab
after immunoprecipitation of HA-tagged Rap1. To corroborate
this finding further, we sought to compare the immunofluores-
cence patterns of Rap1A and AF-6. To this end, a green
fluorescent protein-tagged Rap1AE63 expression construct was
introduced into epithelial MCF7 cells. We selected low
Rap1E63-expressing cells and assessed the distribution of
Rap1E63 as well as its colocalization with endogenous AF-6. As
observed previously by other investigators (6), we noticed that
Rap1A staining is highly reminiscent of a typical Golgi and
vesicular distribution. However, a fraction of the protein can also
be detected clearly at the plasma membrane (see Fig. 2B).
Staining the same cells with an AF-6-directed Ab revealed
colocalization between the two proteins at the plasma mem-
brane, opening the possibility of an interplay between Rap1A
and AF-6 at the plasma membrane. Taken together, these results
suggest that AF-6 is a potential effector, not only of oncogenic
Ras, but also of activated Rap1.
Role of AF-6 in Junctional Complex Organization. As an initial step
toward understanding the role of AF-6, its tissue distribution and
subcellular localization were examined. Takai and coworkers
(16) reported that the rat homologue of AF-6, afadin, exists as
two isoforms: the longer isoform being ubiquitously expressed,
and the shorter being restricted to brain. However, we observed
two bands in dog MDCK and human breast MCF7 epithelial
cells when using Abs raised against human AF-6. Furthermore,
when using the same Abs on a multiple human tissue blot from
lung, kidney, spleen, testis, ovary, heart, and pancreas, we also
noted two bands with molecular masses of approximately 195
and 180 kDa (see Fig. 3 Upper). These data suggest a wider
distribution for the shorter isoform of human AF-6.
As shown in Fig. 3 Lower, AF-6 resides at cell–cell contact sites
in both MDCK and MCF7 cell lines. Because two other labo-
ratories reported tight versus adherens junctional localizations of
human and rat AF-6 proteins, we reassessed its distribution in
MCF7 and MDCK cells. Toward this end, we performed colo-
Fig. 1. Interaction between RasyRap1 and their potential targets. The LexA
two-hybrid tester strain L40 was transformed with plasmids expressing CA Ras
and Rap1 fused to LBD, and their potential targets AF-6, c-Raf, RalGDS, and
d-PI3-kinase (PI3KD) fused to GAD. Transformants were assayed for b-galac-
tosidase expression (Left) and for their ability to grow on medium lacking
histidine (2His; Right).
Fig. 2. (A) Association of Rap1 and full-length AF-6 in vivo in mammalian
cells. Cos1 cells were transfected with myc-tagged full-length AF-6 together
with empty vector, HA-tagged Rap1E63, or HA-tagged RasV12. Protein ex-
pression was confirmed by immunoblotting cell lysates with anti-HA Ab for
detection of Ras and Rap1 and anti-myc Ab for detection of AF-6. Ha-tagged
GTPases were immunoprecipitated with anti-HA Ab, and associated AF-6 was
probed with anti-myc Ab on a Western blot (WB). (B) Comparative localization
of overexpressed Rap1AE63 and endogenous AF-6 in epithelial cells. A cDNA
encoding green fluorescent protein (GFP)-Rap1AE63 was introduced into
MCF7 cells, and the distribution of the GTPase was assessed in vivo by confocal
microscopy. The distribution of endogenous AF-6 was visualized with an
AF-6-specific Ab and rhodamine-conjugated anti-rabbit IgGs.
Fig. 3. (Upper) Distribution of AF-6 in multiple tissues and cell lines. (Lanes 1–7)
A multiple human tissue blot from lung, kidney, spleen, testis, ovary, heart, and
pancreas (Geno Technology, St. Louis) was immunoblotted with anti-AF-6 Ab.
(Lanes 8–11) Immunoblot analysis of MDCK and MCF7 cell lysates with preim-
mune serum (lanes 8 and 10) and anti-AF-6 Ab (lanes 9 and 11), respectively. Two
bands with molecular masses of approximately 195 and 180 kDa (kD) can be seen
(arrows). (Lower) Localization of AF-6 in MDCK and MCF7 cells. Confluent MDCK
and MCF7 cells were stained with rabbit polyclonal Ab against AF-6, followed by
Texas red-conjugated anti-rabbit IgGs.
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calization studies by laser scanning confocal microscopy by using
ZO-1 and b-catenin as markers for tight junctions and adherens
junctions, respectively. Cells were costained with either mono-
clonal anti-ZO-1 and polyclonal anti-AF-6 or monoclonal anti-
b-catenin and polyclonal anti-AF-6, and multiple serial optical
sections were taken from the apical to the basolateral side. Six
serial optical sections (one section every 2 mm) are shown for
each staining (Fig. 4A). Both ZO-1 and AF-6 staining was
concentrated at the apical side of MCF7 cells but with AF-6
having a slightly broader lateral distribution. No AF-6 staining
was observed in more basal sections containing strong b-catenin
staining. Similar observations were made when MDCK cells
were used (data not shown). En face views from stacked serial
sections showed colocalization between AF-6 and ZO-1, which
was not as apparent for AF-6 and b-catenin (Fig. 4B). These data
suggest that AF-6 in MCF7 and MDCK cells colocalizes with
ZO-1 rather than with b-catenin. We want to point out that AF-6
distribution was observed to vary dependent on the adherens
state of the cells. Cells showed increasing intensity of AF-6
staining and membrane localization as they establish full adhe-
rens potential with neighboring cells. In cells that are embedded
in a completely confluent cell layer, the presence of AF-6 in the
cytoplasm appears to increase.
We next wanted to determine whether activated mutant forms
of Ras or Rap1 could influence the localization of AF-6 at the
cell–cell junctions. Toward this end, we created stable MDCK
cell lines expressing either Ha-RasV12 or Rap1E63. We ob-
served that the MDCK Ha-RasV12-expressing cells never
gained a polygonal cell shape, instead maintaining a morphology
more characteristic of fibroblasts and mesenchymal cells. Most
of the cells lost their cell–cell contacts completely or were
associated only loosely with their neighboring cells. In these cells,
AF-6 and ZO-1 staining was absent from the cell borders, and
a diffuse staining was apparent in the cytoplasm (Fig. 4C). In
contrast, Rap1E63-expressing stable MDCK cells displayed a
typical epithelial morphology and the localizations of AF-6 and
ZO-1 in these cells were not perturbed (Fig. 4C). It is noteworthy
that transiently transfected MCF7 cells with high levels of
Rap1E63 expression displayed aberrations from the normally
observed juxtaposed adhering cells.
Identification of Profilin as an AF-6-Binding Protein. The specific
subcellular localization and domain structure of the AF-6 pro-
tein suggest that AF-6 may be a component of a more complex
protein network. To gain further information about unknown
binding partners, we performed a two-hybrid interaction trap
assay by using the C-terminal portion of the protein (amino acids
912–1,612). Independent clones (n 5 2.3 3 106) of a human
Jurkat T cell cDNA library were screened, yielding 530 colonies
that showed prototrophy on medium lacking histidine. Further
analyses of the candidates yielded a major cDNA species that
encoded the small G actin-binding protein profilin. Because all
of the cDNAs carried additional noncoding sequences upstream
of the protein-coding region, we PCR amplified the ORF of
profilin I and fused it to GAD. In addition, the ORF of profilin
II, an isoform that is predominantly expressed in brain tissues,
was amplified from an expressed sequence tag and treated
similarly. Fig. 5 Top summarizes the results of the two-hybrid
assay and indicates that interactions were strongest with mole-
cules containing additional sequences 59 of the profilin-specific
ATG. One reason for this observation may be stabilization of the
overall fold, or alternatively, the epitope interacting with AF-6
could be more favorably positioned. However, both profilin I and
II, the former more pronounced than the latter, bind to the
original bait.
To reevaluate this two-hybrid interaction on a biochemical
level and to map the profilin-binding region within the AF-6
protein, we performed GST pull-down assays. The complete bait
sequence previously used in the two-hybrid screen was fused in
overlapping fragments to GST and expressed in E. coli. Purified
fusion proteins were tested subsequently for their ability to bind
profilin out of an MDCK whole-cell lysate. Two overlapping
fusions retained profilin, as shown by Western blot analysis with
profilin-directed antiserum (Fig. 5 Bottom). This study indicated
that the AF-6-binding site for profilin is located within the
sequence spanned by overlapping fusions (amino acids 977–
1,171 and amino acids 1,083–1,305). Surprisingly, this region
does not contain proline-rich stretches characteristic of profilin-
interacting proteins. However, it does have one copy of a ZPPX
motif at amino acids 1,163–1,166 (Z is a proline, glycine, alanine,
or occasionally a charged residue, and X is preferentially a
hydrophobic residue). This motif was proposed by Witke et al.
(30) to be a feature in a number of profilin-associated proteins.
Furthermore, we were also able to detect an in vivo interaction
between profilin and AF-6. AF-6-bound profilin could be de-
tected with a profilin-directed Ab in an immunoprecipitate
Fig. 4. (A) Confocal images of MCF7 cells comparing the localization of AF-6, ZO-1, and b-catenin. Confluent MCF7 cells were doubly stained with a rabbit
polyclonal Ab against AF-6 and a mouse mAb against ZO-1 or a mouse mAb against b-catenin. As secondary Abs, Texas red-conjugated anti-rabbit IgGs and
FITC-conjugated anti-mouse IgGs were used. Six serial optical sections (one section every 2 mm) are shown for each staining. From left to right, apical to basolateral
side. (B) Localization of AF-6, ZO-1, and b-catenin in confluent control MCF7 cells. As described above, MCF7 cells were costained with a rabbit polyclonal Ab
against AF-6 (a and d) and a mouse mAb against ZO-1 (b) or a mouse mAb against b-catenin (e). AF-6 is shown in red; ZO-1 and b-catenin are shown in green;
and overlay is shown in yellow (c and f ). (C) Localization of AF-6 and ZO-1 in Rap1E63-expressing (g–i) and Ha-RasV12-expressing (j–l) MDCK cells. The indicated
cells were costained with a rabbit polyclonal Ab against AF-6 (g and j) and a mouse mAb against ZO-1 (h and k).
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obtained with a myc Ab from Cos cells transfected with pcDNA-
AF-6-myc (data not shown). The fact that profilin plays an
important role in actin polymerization raises the question as to
whether AF-6, by recruiting profilin, may regulate actin model-
ing proximal to junctional complexes.
Discussion
AF-6 was isolated by virtue of its propensity to interact with
oncogenic Ha-Ras proteins (11, 12). The characterization of the
complete cDNA of human and rodent AF-6 homologues and
subsequent prediction of the motifs arranged therein revealed
two N-terminal RBDs. These motifs, as structural and functional
entities, are also present in other Ras-binding proteins such as
Raf, RalGDS, and Rin-1 (14) and seem to interact specifically
with the activated GTP-bound forms of Ras-GTPases. Because
the effector specificity of a given GTPase is dictated predomi-
nately by the amino acid composition of its effector loop, we
thought it likely that Rap1A, another GTPase, which shares
identical amino acids 32–40 (4), might also associate with AF-6.
In this study, we further dissected the AF-6 N-terminal portion
by separating the predicted RBDs from each other to investigate
their binding potentials for Ras and Rap GTPases. The complete
N terminus, harboring both Ras-binding pockets, was able to
interact with CA Ras and Rap1 GTPases, with the binding to
Rap1A significantly exceeding that to Ha-Ras. This profile was
mimicked and even magnified by RBD1 of AF-6 alone, whereas
RBD2 was virtually incompetent to bind Ras and Rap1A. These
observations stand in agreement with recent in vitro studies
published by Linnemann et al. (31). Based on kinetic and
thermodynamic observations, the authors concluded that the
first 141 amino acids of AF-6 form a complex with CA Rap1A
at higher affinity than with CA Ha-Ras. Whereas it has been
demonstrated that the full-length AF-6 protein can undergo
complex formation with Ha-Ras (27, 29) and with the more
recently identified M-Ras (27) in a cell-based context, this
complex formation remained to be shown for Rap1A. Herein, we
show by coimmunoprecipitation that Rap1A can also tether
full-length AF-6 into a physical complex when coexpressed in
Cos1 cells. Furthermore, we find a certain portion of Rap1A,
when expressed at low levels in epithelial MCF7 cells, to be
present at the plasma membrane where it colocalizes with
endogenous AF-6 protein. These findings, together with the
binding profile described above, is consistent with the concept of
a functional interaction between AF-6 and Rap1A.
Localization studies in MDCK and MCF7 cells revealed that
AF-6 resides in cell–cell junctional complexes. In particular, we
found that, in these cell lines, AF-6 colocalizes with ZO-1 to tight
junctions, consistent with previous studies in MDCK cells (17),
where a direct interaction between AF-6 and ZO-1 was also
reported. Other studies examining mouse small intestinal sec-
tions showed a residency in E cadherin-based adherens junctions
of the rodent homologue afadin (16, 18). This difference in
specific residency between the different systems remains un-
clear. As mentioned above, AF-6 in rats seems to be present in
two isoforms, and the smaller variant, s-afadin, was shown to be
expressed specifically in rat brain (16). However, we observed
that AF-6 and the larger variant are both present in a number of
human tissues and cell lines other than those derived from brain.
Thus, it is likely that a larger F actin-associated isoform of AF-6
in human tissues will serve as a linker molecule between the
membrane and the actin cytoskeleton. With regards to the
shorter isoform, profilin (as discussed below) may mediate a link
to the actin cytoskeleton. Given the localization of AF-6 at
cell–cell junctions and its multidomain structure, it is tempting
to speculate that AF-6 functions as a scaffolding protein involved
in the maintenance, establishment, or function of junctional
complexes. This idea is in favor with the mouse AF-6 loss-of-
function phenotype. Herein, the structural organization of cell–
cell junctions, both of adherens and tight junctions, is abolished,
and the proper progression of embryogenesis is stalled early in
development (32, 33). On a cellular level, the concept of tight
junctions originating from adherens junctions during the process
of polarization is an interesting one (19) and could explain the
disruption of both types of complexes by loss of a single protein.
The fact that AF-6 binds to Ras and even more strongly to
Rap1 raises the question of whether AF-6 is a mediator of Ras,
Rap1, or both signaling pathways. The primary function attrib-
uted to Ras is its role in transformation and differentiation. In
contrast to the well established Raf, RalGDS, and PI3-kinase
molecules, we could not detect any effect of AF-6 on transfor-
mation in a classical foci formation assay (data not shown).
However, a contribution of AF-6 in epithelial transformation can
not be excluded per se. Oncogenic transformation by Ras is also
usually accompanied by a loss of cell–cell adhesion properties
and morphological changes (2); hence, we sought to investigate
whether oncogenic Ras could perturb AF-6 localization. We
observed that the introduction of CA Ha-Ras into MDCK cells
causes disruption of intercellular adhesion architecture. Under
these circumstances, AF-6 and ZO-1 do not accumulate at the
membrane. The precise mechanism by which Ha-Ras elicits this
morphological phenotype remains elusive, and thus far, a pos-
sible model of Ras targeting AF-6 to interfere with cell–cell
adhesion awaits further investigation. A central question in this
context is whether activation of Ras dissociates AF-6 directly
from junctional complexes or whether such a dissociation may be
a secondary effect provoked by events downstream of other
signaling pathways. Nonetheless, hints for a role of AF-6 in Ras
signaling come from Drosophila, where the AF-6 homologue
Canoe has been genetically linked to Ras in the development of
the compound eye (34).
As mentioned earlier, recent studies underline fundamental
differences between Ras and Rap signaling pathways (4, 6). In
Drosophila, Rap1 has been implicated in several aspects of
Fig. 5. Interaction of the C terminus of AF-6 and profilin. (Top) Two-hybrid
interaction. An isolated profilin I cDNA containing an additional leader se-
quence and PCR-amplified profilin I and profilin II cDNAs fused to GAD were
cotransformed with LBD AF-6N into L40 and were assessed for b-galactosidase
expression and for their ability to grow on medium lacking histidine. pLex-
Lamin and pGADGH were used as negative controls. (Middle) Structure of
AF-6. (Bottom) AF-6–profilin association examined in GST pull-down assays.
Overlapping fragments of the AF-6 C-terminal 700 amino acids were ex-
pressed as GST fusions and used to bind profilin from a whole-cell MDCK
lysate. Bound profilin was visualized with an a-profilin Ab in a subsequent
Western blot analysis.
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morphogenesis (9). Its role in mammalian cells, on the other
hand, remains unclear. Rap1A does exhibit some effect on
adhesion, although, thus far, this effect has been shown only for
cell–extracellular matrix interactions (4, 6). CA Rap1A stably
expressed in MDCK cells, in contrast to RasV12, does not give
rise to a disruption of cell–cell contacts, and the infected cells
maintain their epithelial morphology. ZO-1 and b-catenin, as
tight and adherens junctional markers, respectively, remain
associated with their membrane-based complexes, as does AF-6.
Studies assessing the adhesive properties of cells lacking Rap1
function will be required to establish a clear role for Rap1 in
cell–cell adhesion. It is noteworthy, however, that in gastrulating
Drosophila embryos mutant for Rap1, the cell morphology is
greatly impaired. The cells display aberrant shapes, and cell
migration processes are also significantly perturbed (9). Thus, it
is an intriguing possibility that AF-6 may mediate some of Rap1’s
effects on morphogenesis. Whether AF-6 indeed serves as a
bona fide effector molecule for Ras andyor Rap GTPases in vivo
and which developmental or physiological situation might favor
which of the GTPases remain open issues that need more
profound experimentation. Moreover, we can also not exclude
the possibility that AF-6 as a scaffolding molecule may serve to
recruit the GTPases to cell–cell junctions.
To elucidate further the role of AF-6 in junctional structures
and to shed more light on the molecular composition of AF-6-
containing complexes, we set out to isolate other AF-6-binding
proteins. Using two-hybrid techniques, we discovered profilin to
be a binding partner of AF-6 and corroborated this finding in
vitro by mapping a fragment within the AF-6 protein’s C
terminus, C-terminal of the PDZ domain, that retained profilin-
binding activity. AF-6 differs from other profilin ligands such as
VASP (35), MENA (36), diaphanous (37), and the ARP2y3
complex (38, 39) in that it does not interact with profilin via
proline-rich stretches. It does, however, contain repeats of a
ZPPX motif that was proposed as a feature in a number of
profilin-associated proteins by Witke et al. (30) and is present in
the overlap of the two profilin-binding GST fusions amino acids
977–1,171 and amino acids 1,083–1,305 at amino acids 1,163–
1,166. Profilin is an essential element in the actin-assembling
machinery. Its association with monomeric actin and bringing it
to the barbed ends of actin chains seems indispensable for
polymerization (40). Cell–cell adhesion complexes are linked to
a dense filamentous actin network by a number of crosslinking
molecules such as a-catenin, a-actinin, and vinculin in the case
of adherens junctions and ZO-1 in tight junctions. Thus far, actin
polymerization activity has not been ascribed to junctional
complexes, and the possibility that AF-6, by sequestering profilin
to these multiprotein complexes, might indirectly provide such a
function is surely an intriguing one.
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